Dewen Leng, Kai Cao, Qiang Hao, Zhu Peng, Gaofeng Pan, Jing Liu, Jie Yu, Junyi Tang, Jing Li, Han Chen, Huaiwen Chen, Hao Tang
{"title":"用于增强肺癌治疗的 CD133 靶向阿法替尼纳米细胞。","authors":"Dewen Leng, Kai Cao, Qiang Hao, Zhu Peng, Gaofeng Pan, Jing Liu, Jie Yu, Junyi Tang, Jing Li, Han Chen, Huaiwen Chen, Hao Tang","doi":"10.1080/17435889.2024.2422804","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>To develop a novel nanomicelle system to target and eradicate CD133-expressing lung cancer stem cells (CSCs) while imaging lung cancer.</p><p><strong>Methods: </strong>Averatinib nanomicelles with CD133 aptamers incorporated with gadolinium imaging reagents (M-Afa&Gd-CD133) were synthesized. The anticancer and imaging activities of M-Afa&Gd-CD133 were evaluated both in vitro and in vivo.</p><p><strong>Results: </strong>M-Afa&Gd-CD133 efficiently targeted CD133<sup>+</sup> lung CSCs and showed significant antitumor efficacy both in vitro and in vivo. Furthermore, M-Afa&Gd-CD33, as a T1 contrast agent, offers superior and sustained visualization of tumors over an extended period.</p><p><strong>Conclusion: </strong>M-Afa&Gd-CD133 represents a promising strategy for the theranostics of lung cancer.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"2605-2617"},"PeriodicalIF":3.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CD133-targeted afatinib nanomicelles for enhanced lung cancer theranostics.\",\"authors\":\"Dewen Leng, Kai Cao, Qiang Hao, Zhu Peng, Gaofeng Pan, Jing Liu, Jie Yu, Junyi Tang, Jing Li, Han Chen, Huaiwen Chen, Hao Tang\",\"doi\":\"10.1080/17435889.2024.2422804\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>To develop a novel nanomicelle system to target and eradicate CD133-expressing lung cancer stem cells (CSCs) while imaging lung cancer.</p><p><strong>Methods: </strong>Averatinib nanomicelles with CD133 aptamers incorporated with gadolinium imaging reagents (M-Afa&Gd-CD133) were synthesized. The anticancer and imaging activities of M-Afa&Gd-CD133 were evaluated both in vitro and in vivo.</p><p><strong>Results: </strong>M-Afa&Gd-CD133 efficiently targeted CD133<sup>+</sup> lung CSCs and showed significant antitumor efficacy both in vitro and in vivo. Furthermore, M-Afa&Gd-CD33, as a T1 contrast agent, offers superior and sustained visualization of tumors over an extended period.</p><p><strong>Conclusion: </strong>M-Afa&Gd-CD133 represents a promising strategy for the theranostics of lung cancer.</p>\",\"PeriodicalId\":74240,\"journal\":{\"name\":\"Nanomedicine (London, England)\",\"volume\":\" \",\"pages\":\"2605-2617\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanomedicine (London, England)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17435889.2024.2422804\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2422804","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
CD133-targeted afatinib nanomicelles for enhanced lung cancer theranostics.
Aims: To develop a novel nanomicelle system to target and eradicate CD133-expressing lung cancer stem cells (CSCs) while imaging lung cancer.
Methods: Averatinib nanomicelles with CD133 aptamers incorporated with gadolinium imaging reagents (M-Afa&Gd-CD133) were synthesized. The anticancer and imaging activities of M-Afa&Gd-CD133 were evaluated both in vitro and in vivo.
Results: M-Afa&Gd-CD133 efficiently targeted CD133+ lung CSCs and showed significant antitumor efficacy both in vitro and in vivo. Furthermore, M-Afa&Gd-CD33, as a T1 contrast agent, offers superior and sustained visualization of tumors over an extended period.
Conclusion: M-Afa&Gd-CD133 represents a promising strategy for the theranostics of lung cancer.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
